Rhythm Pharmaceuticals Inc. (NASDAQ: RYTM ) shares are trading higher on Wednesday.
RYTM Stock Rises On Expanded IMCIVREE Marketing Authorization
The MHRA this week also granted Imcivree orphan drug designation for acquired HO.
Imcivree initially received marketing authorization in the UK in 2021 for the treatment of obesity and control of hunger in patients with POMC, PCSK1 or LEPR deficiency and in 2022 for patients with Bardet-Biedl syndrome .
In 2024, the MHRA expanded the authorization to include children as young as 2 years old.
RYTM Technical Analysis: Bullish Momentum Near Key Levels
Currently, Rhythm Pharmaceuticals is trading at $116.48, which is 8.2% above its 20-day simple moving average (SMA) of $107.50 and 12.4% above its 50-day SMA of $103.42.
The stock has shown strong momentum, with the moving average convergence divergence (MACD) above its signal line, indicating that downside pressure is easing and momentum is improving.
The stock has recently experienced a golden cross in July, where the 50-day SMA crossed above the 200-day SMA, signaling a bullish trend. Additionally, the stock is currently trading near its 52-week high of $122.20, suggesting that it is in a strong upward trajectory.
Key Resistance: $122.00 — a nearby level where rebounds can stall. Key Support: $100.50 — a nearby level where buyers previously stepped in.Analyst Consensus & Recent Actions: The stock carries a Buy rating with an average price forecast of $143.00. Recent analyst moves include:
JP Morgan: Overweight (Raises Price Forecast to $146.00) (Aug. 7) Citigroup: Buy (Raises Price Forecast to $143.00) (Aug. 5) RBC Capital: Outperform (Raises Price Forecast to $155.00) (Aug. 5)How RYTM Ranks On Momentum In Benzinga Edge
Below is the Benzinga Edge scorecard for Rhythm Pharmaceuticals, highlighting its strengths and weaknesses compared to the broader market:
Momentum: Strong (Score: 74.39) — Stock is outperforming the broader market.RYTM Stock Price Activity: Rhythm Pharmaceuticals shares were up 3.22% at $116.48 at the time of publication on Wednesday, according to Benzinga Pro data .
Image via Shutterstock
Market News and Data brought to you by Benzinga APIs© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
To add Benzinga News as your preferred source on Google, click here .
Posted In: Trading Ideas Movers News General Biotech Health Care Large Cap why it's moving benzai